1. 2007
2. Published

   Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

   Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Nov 2007.

   Research output: Contribution to conference › Paper

3. Published

   The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

   Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Nov 2007.

   Research output: Contribution to conference › Paper

4. Published

   Folate Augmentation of Treatment – Evaluation for Depression (FolATED): protocol of a randomised controlled trial.

   Russell, I. T., Slegg, G. P., Roberts, S. H., Bedson, E., Hughes, D., Lloyd, K., Moat, S., Pirmohamed, M., Slegg, G., Tranter, R., Whitaker, R., Wilkinson, C. & Russell, I., 15 Nov 2007, In: BMC Psychiatry. 7, 1, p. 65

   Research output: Contribution to journal › Article › peer-review

5. Published

   A Global Survey of Antibiotic Leftovers in the Outpatient Setting.

   Hughes, D., Kardas, P., Pechere, J. C., Hughes, D. A. & Cornaglia, G., 1 Dec 2007, In: International Journal of Antimicrobial Agents. 30, 6, p. 530-536

   Research output: Contribution to journal › Article › peer-review

6. Published

   Public meetings of the NICE appraisals committee

   Hughes, D. & Hughes, D. A., 1 Dec 2007.

   Research output: Contribution to conference › Paper

7. Published

   The pharmacokinetic profile of Warfarn: a systematic review

   Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Dec 2007.

   Research output: Contribution to conference › Paper

8. 2008
9. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

10. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

11. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

12. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report